NJBIZ13 小时
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Zacks.com on MSN14 小时
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...
India Today on MSN18 小时
US FDA approves new nasal spray for depression treatment: All about it
The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults ...
Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...
Business Insider India5 年
Regulators just approved a new depression drug with the potential to be a game-changer
Federal regulators have just given the green light to a second new kind of antidepressant this month, after decades of little progress combating the disease. The US Food and Drug Administration on ...
WWNO1 天
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
Medscape17 天
Association of Antipsychotic and Antidepressant Drugs With Q-T interval Prolongation
Purpose: The association of antipsychotic and antidepressant drugs with Q-T ... hepatic insufficiency, and stimulant drug abuse contribute to the risk for developing these arrhythmias, as do ...